ArticleGastroenterology report2019
Vedolizumab for chronic antibiotic-refractory pouchitis.
Article in Gastroenterology report, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2025Pooled it
- AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders.Gastroenterology · 2024Guideline
- Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic Pouchitis? A Systematic Review.Digestive diseases and sciences · 2022Pooled it
- Real-world effectiveness of vedolizumab in refractory pouchitis: a focus on biomarker changes during intravenous to subcutaneous transition (POUCHIVED study).Frontiers in immunology · 2025Observational
- Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review.Iranian journal of medical sciences · 2024Review
- Diagnosis and Medical Treatment of Acute and Chronic Idiopathic Pouchitis in Inflammatory Bowel Disease.Medicina (Kaunas, Lithuania) · 2024Review
- Comprehensive systematic review and pooled analysis of real-world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Managing ulcerative colitis after surgery.Frontiers in medicine · 2022Review
- α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis.Therapeutic advances in gastroenterology · 2021Article
- Pouchitis: Clinical Features, Diagnosis, and Treatment.International journal of general medicine · 2021Review
- Medical treatment of pouchitis: a guide for the clinician.Therapeutic advances in gastroenterology · 2021Review
- Chronic Antibiotic-Refractory Pouchitis: Management Challenges.Clinical and experimental gastroenterology · 2021Review
- #MondayNightIBD: Management of Chronic #Pouchitis.Crohn's & colitis 360 · 2020Article
- Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis.Techniques in coloproctology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic antibiotic-refractory pouchitis (CARP) is a complication of ileal pouch-anal anastomosis (IPAA), which poses a therapeutic challenge. Vedolizumab, a gut-selective monoclonal antibody to the α4β7 of integrin, has been used in such patients, but data on its efficacy are limited. Our aim was to assess the efficacy and safety of vedolizumab as induction therapy in CARP patients.
methodsIn this single-center, historic cohort, patients with CARP who received vedolizumab between January 2015 to June 2017 were identified and analysed. Patients were included if they had active pouchitis with a total of modified pouch disease activity index (mPDAI) score ≥5 or if unavailable clinician diagnosis of active pouchitis. Pre-treatment and at 3-month post-therapy pouchoscopy and clinical visits were used to calculate mPDAI.
resultsA total of 19 patients were included in the study. The mean age was 26.7 ± 12.8 years, with 10 (53%) males. Nine (47%) patients had been treated with anti-tumor necrosis factor (TNF) agents before colectomy and 10 (53%) had anti-TNFs after colectomy and IPAA. Six (32%) patients had improvement in the mPDAI symptom subscores (
conclusionsOur study suggests that vedolizumab has efficacy and can be safely used for CARP patients. Larger studies with a higher number of patients are required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.